This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ohnishi, H. Articles by Chu, T. M. Search for Related Content PubMed PubMed Citation Articles by Ohnishi, H. Articles by Chu, T. M.

Prolongation of Serum Half-Life of Interleukin 2 and Augmentation of Lymphokine-activated Killer Cell Activity by Pepstatin in Mice¹

Department of Diagnostic Immunology Research and Biochemistry, Roswell Park Memorial Institute, Buffalo, New York 14263

We reported previously using a murine model that the kidney is the organ involved in catabolism of exogenous human recombinant interleukin 2 (IL-2) and that cathepsin D, a major renal acid protease, is responsible for the degradation of IL-2. In the present report also using BALB/c mice we have investigated the effect of in vivo pepstatin, an acid protease inhibitor, treatment on serum half-life of IL-2, and generation of lymphokine-activated killer (LAK) cell activity. The in vivo pepstatin treatment by i.p. injection resulted in a significant reduction in the accumulation of ¹²⁵I-IL-2 by the kidney in a reverse dose-response manner. Pepstatin treatment prolonged the serum half-life of ¹²⁵I-IL-2, and the increase in serum half-life of ¹²⁵I-IL-2 was pepstatin dose dependent. A significant reduction in renal cathepsin D activity, as monitored by the degradation of ¹²⁵I-IL-2, was detected. In vivo pepstatin (0.6 mg/kg) treatment along with IL-2 (300,000 IU/mouse) daily for 3 or 6 days resulted in an augmentation of natural killer activity exhibited by freshly prepared and uncultured splenocytes against YAC-1 cells. An additional culturing of the splenocytes with IL-2 (3,000 IU/ml) in vitro for 1 day significantly enhanced the effect of in vivo pepstatin treatment; i.e., LAK cell activity generated from the splenocytes of animals treated with IL-2 plus pepstatin was greatly augmented in comparison with that treated with IL-2 alone. Phenotypic assessment by cell surface markers (Thy-1.2, Lyt-2, L3T4, and asialo-G_M1) on the fresh splenocytes prepared from animals treated in vivo with pepstatin plus IL-2 revealed a decrease in the percentage of cells expressing Thy-1.2 and Lyt-2 and an increase in those carrying asialo-G_M1. These results demonstrated that, as a result of in vivo pepstatin treatment, renal cathepsin D activity was greatly inhibited, which in turn reduced the degradation of circulating IL-2, then prolonged serum half-life of IL-2, and subsequently augmented natural killer and LAK cell activity. The in vivo pepstatin and IL-2 treatment decreased the T-cells and increased the natural killer-like LAK precursor cells, possibly also with an increase in its activity, which were further induced by in vitro IL-2 culture to generate an augmented LAK cell activity. This study also suggests the clinical potential of pepstatin in IL-2-related immunotherapy.

¹ Supported in part by Research Grants IM-416 from the American Cancer Society and R01 CA-37646 from the National Cancer Institute.

² To whom requests for reprints should be addressed.

Received 8/ 8/89. Revised 10/30/89. Accepted 11/ 8/89.

This article has been cited by other articles:

				D. Kamimura, Y. Sawa, M. Sato, E. Agung, T. Hirano, and M. Murakami IL-2 In Vivo Activities and Antitumor Efficacy Enhanced by an Anti-IL-2 mAb J. Immunol., July 1, 2006; 177(1): 306 - 314. [Abstract] [Full Text] [PDF]